BridgeBio Pharma, Inc. — Director's Dealing 2020

Feb 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-02-12

Reporting Person: DANIELS RONALD J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-12	Stock Option (Right to Buy)	$34.65	A	91554	Acquired	2030-02-11	Common Stock (91554)	Direct

Footnotes

F1: The shares subject to this option vest and become exercisable in three annual installments after February 12, 2020, subject to the Reporting Person's continued service to the Issuer through each such vesting date.